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Abstract 
Mycoplasma hyopneumoniae, the causative agent of porcine enzootic pneumonia, colonises the 
respiratory cilia of affected swine causing significant economic losses to swine production worldwide. 
Heparin is known to inhibit adherence of M. hyopneumoniae to porcine epithelial cilia. M. hyopneumoniae 
cells bind heparin but the identity of the heparin-binding proteins is limited. Proteomic analysis of M. 
hyopneumoniae lysates identified 27 kDa (P27), 110 kDa (P110) and 52 kDa (P52) proteins representing 
different regions of a 159 kDa (P159) protein derived from mhp494. These cleavage fragments were 
surface located and present at all growth stages. Following purification of 4 recombinant proteins 
spanning P159 (F1P159, F2P159, F3P159, and F4P159), only F3P159 and F4P159 bound heparin in a 
dose-dependent manner (Kd values 142.37 + 22.01 nM; 75.37 + 7.34 nM respectively). Scanning electron 
microscopic studies showed M. hyopneumoniae bound intimately to porcine kidney epithelial-like cells 
(PK15 cells) but these processes were inhibited by excess heparin and F4P159. Similarly, latex beads 
coated with F2P159 and F4P159 adhered to and entered PK15 cells, but heparin, F2P159, and F4P159 
was inhibitory. These findings indicate that P159 is a post-translationally cleaved, glycosaminoglycan-
binding adhesin of M. hyopneumoniae. 
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Mycoplasma hyopneumoniae, the causative agent of porcine enzootic pneumonia, colonises the 21 
respiratory cilia of affected swine causing significant economic losses to swine production 22 
worldwide. Heparin is known to inhibit adherence of M. hyopneumoniae to porcine epithelial 23 
cilia. M. hyopneumoniae cells bind heparin but the identity of the heparin-binding proteins is 24 
limited. Proteomic analysis of M. hyopneumoniae lysates identified 27 kDa (P27), 110 kDa 25 
(P110) and 52 kDa (P52) proteins representing different regions of a 159 kDa (P159) protein 26 
derived from mhp494. These cleavage fragments were surface located and present at all growth 27 
stages. Following purification of 4 recombinant proteins spanning P159 (F1P159, F2P159, F3P159, 28 
and F4P159), only F3P159 and F4P159 bound heparin in a dose-dependent manner (Kd values 142.37 29 
+ 22.01 nM; 75.37 + 7.34 nM respectively). Scanning electron microscopic studies showed M. 30 
hyopneumoniae bound intimately to porcine kidney epithelial-like cells (PK15 cells) but these 31 
processes were inhibited by excess heparin and F4P159. Similarly, latex beads coated with F2P159 32 
and F4P159 adhered to and entered PK15 cells, but heparin, F2P159, and F4P159 was inhibitory. 33 
These findings indicate that P159 is a post-translationally cleaved, glycosaminoglycan-binding 34 






Mycoplasma hyopneumoniae, the etiological agent of enzootic pneumonia (EP), ranks as one of 39 
the most economically significant diseases affecting swine production worldwide. The initial 40 
event in colonization of the respiratory tract by M. hyopneumoniae is binding to respiratory cilia 41 
(Blanchard et al., 1992; Mebus and Underdahl, 1977; Tajima and Yagihashi, 1982). 42 
Colonisation disrupts the mucociliary escalator through ciliostasis, loss of cilia, and epithelial 43 
cell death (DeBey and Ross, 1994). Acute inflammation of airways surrounding the site of 44 
infection leads to epithelial hyperplasia and infiltration of the lamina propria by inflammatory 45 
cells composed largely of neutrophils and mononuclear cells (Livingston et al., 1972). Disease 46 
resolution occurs only after a prolonged period (if at all) and once infected, swine remain 47 
recalcitrant to reinfection (Kobisch et al., 1993). Most cases of EP are chronic, and are often 48 
complicated by secondary bacterial infections which exacerbate morbidity and mortality 49 
(Ciprian et al., 1988). M. hyopneumoniae also plays a major role in the porcine respiratory 50 
disease complex in countries where infections with porcine respiratory and reproductive 51 
syndrome virus complicate respiratory disease pathology (Thacker et al., 2000). Collectively, 52 
these observations indicate that losses in swine production due to this pathogen are likely to be 53 
considerably underestimated. 54 
 Genome sequence information for several strains of M. hyopneumoniae has 55 
facilitated proteomic studies and provided insight into families of molecules likely to play a role 56 
in the disease process (Djordjevic et al., 2004; Minion et al., 2004; Vasconcelos et al., 2005). 57 
These advances are significant given that overall poor growth on agar surfaces coupled with a 58 
lack of development of genetic tools to selectively mutate target genes has for many years 59 
hampered efforts to identify molecules that play fundamental roles in pathogenesis (Minion, 60 
2002). The cilium adhesin, P97 is the only cell surface adhesin that has been extensively 61 
characterized in M. hyopneumoniae (Hsu and Minion, 1998; Minion et al., 2000). P97 is 62 
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extensively cleaved post-translationally during growth in vitro and processing is strain-specific. 63 
Most cleavage products remain associated with the M. hyopneumoniae cell surface despite the 64 
absence of hydrophobic domains or other motifs that might act to anchor these fragments to the 65 
cell membrane (Djordjevic et al., 2004). Protein-protein interactions either with other M. 66 
hyopneumoniae proteins and/or with host-derived molecules may facilitate the localization of 67 
these cleavage fragments to the cell surface (Djordjevic et al., 2004). The p97 gene (mhp183) 68 
forms part of a two gene operon with p102 (mhp182) (Adams et al., 2005; Hsu and Minion, 69 
1998). The M. hyopneumoniae genome contains six paralogs of p97 and six of p102 (Minion et 70 
al., 2004) many of which occur as two-gene operons containing a p97 and p102 paralog (Adams 71 
et al., 2005).  72 
Attachment of  M. hyopneumoniae to respiratory cilia is a necessary prerequisite for 73 
epithelial damage (DeBey and Ross, 1994). Monoclonal antibodies F1B6 and F2G5, which 74 
recognise the R1 cilium binding region in P97 (Zhang et al., 1995), are able to reduce adherence 75 
of M. hyopneumoniae to respiratory cilia by approximately 70%. Purified recombinant P97 76 
inhibits adherence of M. hyopneumoniae cells to cilia in a dose-dependent manner (Zhang et al., 77 
1995) and binding of recombinant P97 to porcine respiratory cilia is inhibited by sulfated 78 
glycosaminoglycans (Hsu et al., 1997). Consistent with these observations, P97 was recently 79 
shown to possess two heparin-binding domains (Jenkins et al., 2006). Heparin, dextran sulfate, 80 
chondroitin sulfate, laminin, mucin and fucoidan also inhibit the ability of M. hyopneumoniae to 81 
bind respiratory cilia (Zhang et al., 1994). The ability to bind glycosaminoglycans is likely to 82 
arm M. hyopneumoniae with the capability to bind a variety of important host molecules 83 
(Duensing et al., 1999; Menozzi et al., 2002; Patti et al., 1994; Wadstrom and Ljungh, 1999) 84 
that also possess glycosaminoglycan binding capabilities, and thus circumvents the need to 85 
evolve specific receptors that target these molecules (Jenkins et al., 2006). Although these 86 
experiments indicate that heparin-binding surface proteins are likely to be important in 87 
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pathogenesis, knowledge of heparin-binding surface proteins (apart from P97) of M. 88 
hyopneumoniae is lacking.  89 
The observation that P97 is extensively modified by proteolytic cleavage suggests that 90 
other molecules secreted to the surface of M. hyopneumoniae may also be modified in a similar 91 
fashion. In this study we characterize a gene known as mhp494 (Minion et al., 2004) that 92 
encodes a protein with a putative mass of 159 kDa (P159). We show that P159 undergoes post-93 
translational proteolytic cleavage, generating a complex pattern of fragments that reside on the 94 
surface of M. hyopneumoniae. We examined the ability of M. hyopneumoniae cells to bind 95 
heparin and used a porcine epithelial-like cell line (PK15 cells) previously shown to bind M. 96 
hyopneumoniae (Zielinski et al., 1990) to develop a assay to identify new adhesins and study 97 
pathogen adherence to these cells. We show that M. hyopneumoniae binds intimately to PK15 98 
cells and that this ability is inhibited by pre-incubating M. hyopneumoniae with heparin. To 99 
understand the role that cleavage fragments of P159 play in binding heparin and adhering to 100 
PK15 cells, latex beads coated with recombinant fragments spanning different regions of this 101 
molecule were constructed and examined in our assay. Our findings indicate that P159 is a novel 102 
glycosaminoglycan binding adhesin of M. hyopneumoniae and that regions within P159 play a 103 
role in adherence to PK15 cells. 104 
 105 
Results 106 
Expression pattern of P159 in M. hyopneumoniae strain 232 107 
The deduced amino acid sequence of p159 (GenBank accession number AAV27918, mhp494) 108 
comprised 1410 amino acids with a predicted pI of 8.42. p159 is a novel gene and its location in 109 
the genome is unusual in that it forms part of two gene structure with a p97 paralog identified 110 
here as p216 (mhp493; Minion et al., 2004). An ongoing comprehensive peptide mass mapping 111 
study of M. hyopneumoniae has resolved three groups of protein spots (see boxed regions in Fig. 112 
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1A) with apparent molecular masses of 27 (P27), 52 (P52) and 110 (P110) kDa that represented 113 
different regions spanning P159. To confirm the identity of the P159 fragments, 2-D 114 
immunoblots of whole cell lysates of M. hyopneumoniae probed with a pool of antisera raised to 115 
recombinant fragments F1P159-F4P159 spanning P159 (see fig. 1C) identified P159 fragments 116 
shown in Fig. 1 (data not shown). TMpred analysis 117 
(www.ch.embnet.org/software/TMPRED_form.html) of P159 identified a single, putative 118 
transmembrane region (score 2150) between amino acids 9-29 (Fig. 1B). N-terminal sequence 119 
analysis of P27 identified a peptide sequence corresponding to the first 7 amino acids 120 
(MKKQIRN) of P159. Assuming P159 is a surface antigen (see later), this data suggests that the 121 
transmembrane domain is not removed when the P159 preprotein is secreted to the cell surface.  122 
Based on peptide mass mapping and N-terminal sequence analyses, P27 (observed pI 123 
~10) spans between amino acids 1-219 of the P159 sequence and cleavage at amino acid 220 124 
would generate a protein fragment with a predicted mass of 24.5 kDa and a pI of 9.12 (Fig. 1B). 125 
Peptide mass matches of protein spots representing P52 and P110 spanned amino acids 978-126 
1387 and 303-841 respectively (Fig. 1B) indicating that a cleavage event occurred between 127 
amino acids 220-302 and between amino acids 842-977. To generate the P110 fragment, 128 
cleavage events at amino acids 220 and 977 would generate a protein with a mass of 84.8 kDa 129 
(pI of 6.28); cleavage at amino acids 303 and 841 would generate a peptide of 60.5 kDa (pI of 130 
8.81). Protein spots representing P110 migrate with a pI between 6-6.5 suggesting that two 131 
cleavage events probably occurred near amino acids 220 and 977. In either case, P110 has a 132 
predicted mass ranging between 61 and 85 kDa indicating that this protein fragment migrates 133 
aberrantly during SDS-PAGE. Amino acids 736-977 representing the predicted C-terminal 134 
region of P110 are enriched in acidic residues (predicted pI of 5.01) and P159 fragments such as 135 
P110 that span this region are expected to migrate with a more acidic pI compared to P27 and 136 
P52 (pI 8.85). The presence of this region in P110 is likely to contribute to its aberrant migration 137 
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during SDS-PAGE. Assuming the first cleavage scenario is correct, P52 would span amino acids 138 
977-1410 generating a protein with a predicted mass of 49 kDa. This is largely consistent with 139 
the size and pI of P52 shown in Fig. 1A. Attempts to generate N-terminal sequence by Edman 140 
degradation for P110 and P52 cleavage fragments were unsuccessful. Collectively, these data 141 
suggest that P159 is rapidly processed during secretion to the cell surface (see later).  142 
 143 
Purification and western blot analysis of P159 fragments  144 
To examine the function(s) of regions within P159, four non-overlapping regions spanning the 145 
entire molecule (Fig. 1C) were cloned and expressed as poly-histidine fusion proteins in 146 
Escherichia coli: F1P159, F2P159, F3P159, and F4P159 comprising amino acids 31-264, 265-519 558-147 
909 and 958-1405, respectively.  F1P159-F4P159 were readily expressed and purified by Nickel-148 
NTA agarose affinity chromatography (Fig. 2, panels A-D). The central region of P159 149 
representing P110 and spanning amino acids 265-909 was cloned as two separate fragments 150 
(F2P159 and F3P159) because previous experience of cloning large mollicute genes in Escherichia 151 
coli typically resulted in an extremely poor protein yield and/or multiple translation products 152 
presumably due to the high A+T content of mycoplasmal genes (Notarnicola et al., 1990). 153 
Attempts to clone and express the entire p159 gene into E. coli were unsuccessful.  154 
Rabbit antisera raised separately to purified recombinant fragments F1P159-F4P159 (Fig. 155 
1C) were used to further investigate the post-translational cleavage pattern of P159 and to 156 
determine their cellular location. Antiserum raised against F1P159 (which spans P27) reacted 157 
strongly with purified recombinant F1P159 (Fig. 2, panel A lane 2) but reacted poorly with P27 in 158 
cell lysates of M. hyopneumoniae (Fig. 2, panel A, lane 1). Although the poly-histidine tag 159 
engineered into the N-terminus will contribute to the increased size of F1P159 compared to P27, it 160 
is unlikely to account for the 4 kDa difference in apparent mass of these two proteins. Of note, 161 
the N-terminal 22-kDa cleavage fragment of the cilium adhesin P97 was also not easily detected 162 
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by immunoblotting (Djordjevic et al., 2004). These data suggest that small cleavage fragments 163 
containing intact transmembrane domains may bind poorly to PVDF membrane. As expected 164 
both F2P159 and F3P159 antisera (which span P110) identified P110 (Fig. 2, panel B and C, lane 165 
1). However these sera also detected a second protein with a predicted mass of approximately 68 166 
kDa (P68) which probably represents an additional cleavage product of P159 so far undetected 167 
in our proteomic analyses (see also Fig. 2 panel E). Anti-F4P159 serum (which spans P52) reacted 168 
with a M. hyopneumoniae protein equivalent in size to P52 (panel D, lane 1). Interestingly, anti-169 
F4P159 serum also strongly recognized a higher mass protein (> 118 kDa) when reacted with an 170 
affinity purified preparation of recombinant F4P159 (Fig. 2, panel D, lane 2). Peptide mass 171 
mapping analysis of this higher mass protein matched the C-terminal 52 kDa region of P159 172 
indicating that this represents an SDS-PAGE-stable, multimeric form of F4P159 (data not shown). 173 
The higher mass form of F4P159 was also recognized by commercial anti-poly-histidine antisera 174 
further supporting this interpretation (data not shown). Whether this multimeric form of P52 175 
plays a role in the biology of M. hyopneumoniae remains unknown.   176 
To examine the immunoblot profile of P159 during different stages of growth in vitro, 177 
synchronised cultures of M. hyopneumoniae collected between 8 h (early log phase) and 72 h 178 
(late stationary phase) post-inoculation were reacted with a pool of F1P159-F4P159 antisera. A 179 
consistent pattern of three strongly staining fragments of masses 52, 68, and 110 kDa 180 
(representing P52, P68 and P110) were detected at all time points suggesting that P159 is 181 
processed in an identical fashion during early log (8 h), mid-log (16-28 h) and stationary phases 182 
(40-72 h) of growth in vitro (Fig. 2 panel E). The P159 pre-protein was not detected suggesting 183 
that it is rapidly processed. Immunoblot profiles of whole cell lysates representing different 184 
strains of M. hyopneumoniae, when reacted with a pool of anti F1P159-F4P159, showed similar yet 185 
distinct patterns suggesting that strain-specific cleavage events occur (Fig. 2F).   186 
 187 
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Trypsin sensitivity and immuno-electron microscopy analysis of P159 188 
To determine if P159 cleavage fragments are surface accessible, freshly cultured M. 189 
hyopneumoniae strain 232 cells were exposed to concentrations of trypsin ranging from 0-150 190 
μg/ml. Exposure of intact M. hyopneumoniae cells to trypsin concentrations from 0.1-3 μg/ml 191 
showed a gradual loss of P68 and P110; these two proteins being almost completely digested at a 192 
trypsin concentration of 10 μg/ml. P52 was the most resilient fragment and was detectable at a 193 
trypsin concentration of 10 μg/ml but completely degraded with 50 μg/ml. There was no 194 
evidence of any P159 cleavage fragment at trypsin concentrations above 50 μg/ml (Fig. 3A). The 195 
digestion kinetics shown in Fig. 3A are similar to those of the cilium adhesin fragments that are 196 
known to reside on the cell surface (Djordjevic et al., 2004) indicating that processed P159 197 
fragments are likely to also reside on the surface of M. hyopneumoniae. Control experiments 198 
using antisera raised against recombinant ribosomal protein L7/L12 (shown to reside in the 199 
cytosol; Burnett et al., unpublished results), pyruvate dehydrogenase subunits A and D and 200 
lactate dehydrogenase (previously shown to reside in the cytosol) were resistant to trypsin 201 
concentrations up to 300 μg/ml (data not shown; Djordjevic et al., 2004).  202 
To confirm the surface location of P159 fragments, immuno-electron microscopy was 203 
conducted using F1P159-F4P159 antisera. F2P159 and F4P159 antisera clearly showed that P159 204 
fragments P110 and/or P68 and P52 recognized by these antisera reside on the surface of M. 205 
hyopneumoniae strain 232 (Fig. 3C and 3E). Control sera collected prior to immunisation with 206 
recombinant fragments reacted poorly with M. hyopneumoniae cells (Fig. 3B and 3D). We were 207 
unable to generate reliable images using antisera raised against F1P159 and F3P159 proteins 208 





M. hyopneumoniae binds heparin 213 
Various glycosaminoglycans have been shown to interfere with the ability of M. hyopneumoniae 214 
to adhere to porcine cilia (Zhang et al., 1994). Fig 4A shows that biotinylated heparin binds to 215 
the surface of freshly cultured cells of M. hyopneumoniae strain 232 in a dose dependent and 216 
saturable manner. M. hyopneumoniae strain 232 proteins ranging in mass from 15 to 150 kDa 217 
bind biotinylated heparin (Fig. 4B).  218 
 219 
Domains within P159 bind heparin 220 
With the aim of determining the function(s) of P159 and specifically determine if any of its 221 
cleavage fragments bind heparin, a panel of extracellular matrix (ECM) components (including 222 
fibronectin, laminin, collagen and fibrinogen) and various glycosaminoglycans (including 223 
heparin, heparan sulfate, mucin, chondrotin sulfate A and B and fucoidan), were tested for either 224 
their ability to bind directly to recombinant fragments of P159, or to interfere with binding to 225 
one of these components. Although none of the recombinant fragments bound any of the ECM 226 
proteins, F3P159 and F4P159 bound biotinylated heparin in a saturable and dose-dependent manner 227 
with saturation occurring between 15-20 μg/ml (0.5-1.5 μM) of biotinylated heparin. A 50-fold 228 
excess of unlabelled heparin was found to extinguish > 90% of the signal (Fig. 5) indicating that 229 
heparin occupies specific binding sites on both F3 and F4. Non-linear regression and one-site 230 
binding analyses were performed on the specific binding data producing an estimate of the 231 
apparent dissociation constants for F3P159- and F4P159- biotinylated heparin complexes of 142.37 232 
+ 22.01 nM (2.13 + 0.44 μg/ml) and 75.37 + 7.34 nM (1.13 + 0.11 μg/ml) respectively. To 233 
further investigate the interaction of F3 and F4 with heparin, binding of these proteins to a 234 
heparin-agarose (Sigma-Aldrich, St. Louis, Missouri) column was investigated. Both F3P159 and 235 
F4P159 bound to the heparin-agarose column and were eluted with 10 mM Tris containing 236 
approximately 0.22 M NaCl and 0.32 M NaCl respectively (data not shown).  237 
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The kinetics of binding biotinylated heparin by F3P159 and F4P159 was examined in more 238 
detail.  At concentrations between 1-250 μg/ml, heparin profoundly affected the ability of F3P159 239 
and F4P159 to bind biotinylated heparin with concentrations > 500 μg/ml effectively blocking 240 
binding (Fig. 6A). Non-linear regression with one-site competition determined the 50% 241 
inhibitory concentration (IC50) for F3P159 and F4P159 to be 52.92 + 1.03 μg/ml and 66.63 + 1.02 242 
μg/ml, respectively. Various glycosaminoglycans were tested for their ability to inhibit the 243 
binding of F3P159 and F4P159 to biotinylated heparin (Fig. 6B and C). Fucoidan, a highly sulfated 244 
fucose polymer, effectively inhibited the binding of both F3P159 and F4P159 to biotinylated 245 
heparin with IC50 values of 96.28 + 1.19 μg/ml and 36.23 + 1.14 μg/ml, respectively. Heparan 246 
sulfate, chondroitin sulfate A, chondroitin sulfate B (Fig. 6), and mucin (results not shown) were 247 
unable to inhibit the binding of F3P159 or F4P159 to biotinylated heparin.  248 
 249 
Adherence and invasion of PK15 cell monolayers by M. hyopneumoniae.  250 
Radiolabelled M. hyopneumoniae strains J, 232 and 144L have previously been shown to adhere 251 
to a porcine kidney epithelial-like (PK15) cell line in a receptor-dependent manner and their 252 
adherence was blocked by either pre-treating PK15 cells with unlabelled M. hyopneumoniae or 253 
by pre-treating M. hyopneumoniae cells suspensions with trypsin (Zielinski et al., 1990). In our 254 
study we examined the ability of M. hyopneumoniae strain J cells to interact with PK15 cell 255 
monolayers by scanning electron microscopy. We showed that M. hyopneumoniae adheres 256 
intimately to the surface of PK15 cells with the mycoplasma often seen closely associated with 257 
microvilli on the surface of the monolayers (Fig. 7A). M. hyopneumoniae cells were separately 258 
pre-incubated with recombinant fragments F1P159-F4P159 prior to addition to PK15 cells to 259 
determine if regions within P159 influence the ability of mycoplasma cells to bind to the 260 
monolayers. When M. hyopneumoniae cells were pre-incubated with 1 μg of F4P159 protein [and 261 
not F1P159, F2P159 or F3P159, (data not shown)], an obvious decrease in adherence was observed 262 
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(Fig. 7B). M. hyopneumoniae cells pre-incubated with a saturating concentration of heparin (500 263 
μg/ml) also bound poorly to the surface of PK15 cell monolayers (Fig. 7C). Purified 264 
immunoglobulins (25 μg) from serum obtained from rabbits separately immunized with F1P159, 265 
F2P159, F3P159 and F4P159 proteins did not appear to affect the ability of M. hyopneumoniae to 266 
adhere to PK15 cells or the uptake and entry of latex beads (see later) coated with P159 267 
recombinant fragments (data not shown). 268 
To define domains within P159 that might play a role in adherence to PK15 cells, a latex 269 
bead binding assay was used. Adherence was observed by a combination of double-270 
immunofluorescence microscopy (Fig. 8) and scanning electron microscopy (Fig. 9). Latex 271 
beads separately coated with F2P159, F3P159 and F4P159 were found to adhere to PK15 cells within 272 
2 h incubation at 37˚C (Fig. 8). Furthermore, latex beads coated with F2P159 and F4P159 (but not 273 
F1P159 or F3P159) were detected inside PK15 cells (Fig. 8 see arrows) between 2-22 h post-274 
incubation and increasing numbers of internalized beads were detected over this time (results not 275 
shown). Latex beads alone (data not shown) or beads coated with recombinant F1P159 protein 276 
(Fig. 8A) did not adhere to or enter PK15 cells.   277 
To examine the specificity of binding of F1P159 - F4P159 - coated latex beads to PK15 278 
cells, binding experiments using latex beads that had been separately pre-incubated with 279 
recombinant P159 fragments (1 μg each) were performed and examined by scanning electron 280 
microscopy. In preliminary experiments, pre-incubation with soluble F2P159, F3P159 and F4P159 281 
reproducibly decreased the attachment of F2P159 - (Fig. 10A), F3P159 - (data not shown) and 282 
F4P159 - (Fig. 10B) coated latex beads to PK15 cells. Similarly, when F4P159-coated latex beads 283 
were pre-incubated with heparin they poorly bound to PK15 cell monolayers (Fig. 10C and D). 284 
The effect of pre-incubating F2P159 - and F4P159 - coated latex beads separately with heparin and 285 
with excess F2P159 and F4P159 proteins on their ability to adhere to and enter PK15 cells is 286 
summarized in Fig. 10D. Pre-incubation of F2P159 - and F4P159 - coated latex beads with a 287 
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saturating concentration of heparin inhibited binding to PK15 cells by 89 and 64% respectively 288 
(Fig. 10D). Significantly, heparin completely abolished entry of F2P159 - and F4P159 - coated latex 289 
beads into PK15 cells (Fig. 10D). Pre-incubation of F4P159-- coated latex beads with excess 290 
F4P159 inhibited the binding and entry of F4P159 - coated latex beads by 71% and 67% 291 
respectively and displayed the greatest ability of all the P159 recombinant proteins to inhibit the 292 
binding and invasion of latex beads coated with recombinant P159 proteins (Fig. 10D).   293 
 294 
Discussion 295 
mhp494 encodes a protein with a predicted mass of 159 kDa (P159) and is unusual in 296 
that it forms part of a two gene structure with mhp493, a putative cilium adhesin paralog 297 
(Minion et al., 2004). MALDI-TOF mass spectrometric analyses of M. hyopneumoniae proteins 298 
separated by 2-D gel electrophoresis identified proteins with masses of 27, 52 and 110 kDa that 299 
represented regions within P159. Immunoblotting studies using monospecific antisera raised to 300 
different regions of mhp494 readily identified these and other proteins (putative cleavage 301 
fragments) with masses between 27-110 kDa in whole cell lysates of M. hyopneumoniae 302 
harvested during early, mid, late exponential and stationary phases of growth indicating that 303 
P159 is extensively cleaved post-translationally. A high mass protein that might represent P159 304 
was virtually undetectable by immunoblotting indicating that P159 is rapidly processed, 305 
probably by a proteolytic enzyme(s). Trypsin digestion studies confirmed that the majority of 306 
these cleavage fragments reside on the cell surface despite the absence of hydrophobic stretches 307 
of amino acids that might anchor these peptides to the cell membrane. The N-terminal sequence 308 
MKKQIRN (amino acids 1-7 in Mhp494) obtained from the N-terminal cleavage fragment P27 309 
precedes the only significant transmembrane domain in P159 (amino acids 9-29; TMpred score 310 
2150) consistent with a hypothesis that cleavage occurs simultaneously with or immediately 311 
after translation and secretion to the cell surface.  312 
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These observations bear a striking resemblance to those reported for the cilium adhesin 313 
P97 (mhp183); i) the P126 pre-protein is barely detectable by immunoblot and is extensively 314 
cleaved, generating fragments ranging in mass from 20-120 kDa (Djordjevic et al., 2004), ii) the 315 
N-terminal cleavage fragment P22 contains the only significant transmembrane domain found in 316 
the molecule, yet many of the cilium adhesin cleavage fragments are present on the cell surface 317 
and iii) processing is strain-specific. These observations suggest that P159 and P126 pre-proteins 318 
are processed via the same pathway. Although the surface topography of M. hyopneumoniae is 319 
poorly understood we have now provided evidence that three high-mass surface proteins of M. 320 
hyopneumoniae P159 (this study; mhp494), P97 (mhp183) and P102 (mhp182) (Djordjevic et 321 
al., 2004) are cleaved with fragments residing on the cell surface. No evidence for proteolytic 322 
processing was reported for two well characterized surface lipoproteins with masses of 65 kDa 323 
(Kim et al., 1990) and 46 kDa (Futo et al., 1995). These data suggest that surface molecules 324 
secreted via type II but not type I secretory pathways may be targeted for further proteolytic 325 
processing in M. hyopneumoniae but additional studies are needed to rigorously test this 326 
hypothesis. The identity and specificity of the corresponding protease(s) that cleave these 327 
proteins remains unknown. However, bioinformatic analysis of the M. hyopneumoniae genome 328 
identified five proteins with aminopeptidase signatures (mhp209, Map; mhp462, PepA; mhp520, 329 
PepF; mhp680, PepP; and mhp656, Gcp) and a further two with serine protease signatures 330 
(mhp287 and mhp292). One or several of these are suspected of playing a role in surface protein 331 
processing.   332 
 BlastP analyses showed that mhp494 is a novel molecule with discrete regions showing 333 
limited homology to proteins found in Mycoplasma conjunctivae and M. hyopneumoniae. 334 
Specifically, two regions spanning amino acids 1004-1406 and 2-200 of P159 showed 22% 335 
identity (41% similarity) and 25% identity (46% similarity) respectively with LppT from 336 
Mycoplasma conjunctivae (Belloy et al., 2003). lppT is the second gene in a two-gene operon 337 
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with lppS which was reported to be an adhesin in this species (Belloy et al., 2003). Furthermore, 338 
amino acids 1026-1165 displayed 26% identity (48% similarity) with mhp182 (P102) and amino 339 
acids 10-209 and 17-191 showed 28% identity (51% similarity) and 28% identity (44% 340 
similarity) with P102 paralogs mhp272 and mhp384 respectively.  341 
Different strains of M. hyopneumoniae have been shown to adhere to PK15 cell 342 
monolayers (Zielinski et al., 1990) but in that study adherence was monitored by counting 343 
radiation emitted from radiolabelled adhering cells. Scanning electron microscopy studies 344 
reported here show that M. hyopneumoniae strain J adheres intimately to PK15 cells especially 345 
in regions where microvilli are prominent. Pre-incubating M. hyopneumoniae cells with a 346 
saturating concentration of heparin almost completely abolished binding to PK15 cells, 347 
underscoring the importance that heparin binding proteins on the surface of M. hyopneumoniae 348 
play in adherence to eukaryote cells. Importantly, Zhang et al. (1994) showed that heparin 349 
significantly inhibited the ability of M. hyopneumoniae to adhere to preparations of porcine 350 
respiratory tract cilia. Collectively, these studies indicate that PK15 cell monolayers provide a 351 
useful model system for identifying adhesins in M. hyopneumoniae. To this end we showed that 352 
P159 recombinant fragments F2P159 and F4P159 (and to a limited extent F3P159) which span all but 353 
the N-terminal 27 kDa of P159 promote the ability of latex beads to bind to PK15 cells 354 
demonstrating that P159 is a novel eukaryote cell adhesin. Pre-incubation of F2P159– and F4P159–355 
coated latex beads with a saturating concentration of heparin significantly blocked the ability of 356 
these beads to adhere to, and completely abolished their entry into, PK15 cells.  357 
Recombinant fragments F3P159 and F4P159, which span the C-terminal half of P159, were 358 
found to bind heparin in a dose-dependent, saturable and specific manner (Kd values of 142.37 + 359 
22.01 nM and 75.37 + 7.34 nM respectively). F3P159 and F4P159 were also shown to bind to 360 
heparin-agarose showing that these P159 recombinant fragments bind both soluble and bound 361 
heparin. These values are comparable to other biologically significant heparin-protein binding 362 
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interactions (Pethe et al., 2000) and fall in the midrange of other reported constants for heparin-363 
protein interactions (Pankhurst et al., 1998). The ability of F2P159 to promote the adherence of 364 
latex beads to PK15 cells despite an inability to bind heparin suggests that different regions 365 
within P159 use different mechanisms to bind eukaryote cells. Our data suggests that P159 366 
cleavage fragments P110 and P52 each possess the ability to bind heparin and to adhere to PK15 367 
cells; the function of F1P159 remains unknown. M. hyopneumoniae cells pre-incubated with an 368 
excess of F4P159 protein were significantly affected in their ability to adhere to PK15 cells 369 
suggesting that the C-terminal region of P159 spanning P52 interacts with a receptor(s) on the 370 
surface of PK15 cells. Further processing events that affect the integrity of P110 and P52 may 371 
have important ramifications for their biological function. Immunoblotting studies (Fig. 2) 372 
indicate that P68 resides within P110 and further studies are needed to examine the biological 373 
properties specific to this fragment.  374 
It is becoming evident from this and previous studies (Djordjevic et al., 2004; Jenkins et 375 
al., 2006) that M. hyopneumoniae processes key surface proteins to generate domains with 376 
potentially important biological functions. Processing of surface proteins may provide M. 377 
hyopneumoniae with a means to regulate its surface architecture enabling it to adapt to various 378 
tissue environments within the host. Cytokines, growth factors, complement components, plasma 379 
lipoproteins, regulators of homeostasis, and various extracellular matrix components such as 380 
vitronectin and fibronectin have been shown to bind heparin (Bernfield et al., 1999; Jackson et 381 
al., 1991; Kim et al., 1990). Microbial pathogens bind heparin and related glycosaminoglycans 382 
as a means of recruiting a wide variety of mammalian heparin binding proteins to their surface, 383 
thus bypassing the need to evolve specific receptor molecules for these key mammalian proteins 384 
(Duensing et al., 1999). More importantly, the ability to recruit these proteins to the surface of 385 
microbial pathogens impacts on key aspects of microbial pathogenicity such as an increased 386 
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capacity to invade epithelial cells and inhibition of chemokine-induced chemotaxis (Duensing et 387 
al., 1999).  388 
The ability of a protein to bind glycosaminoglycans largely depends on electrostatic 389 
interactions between the negatively charged sulfate groups and positively charged regions of the 390 
protein; the role of different sugar moieties in the backbone of the glycosaminoglycan in protein 391 
binding is less well understood. Although the heparin-binding motifs, XBBXBX and 392 
XBBBXXBX (where B represent basic amino acids and X any other amino acids) have been 393 
known for many years (Cardin and Weintraub, 1989), more recent studies indicate that various 394 
combinations of clustered basic amino acids can bind heparin (Aoki et al., 2004). P159 is rich in 395 
lysine (K) and arginine (R) residues (15.6% and 13.9% of F3P159 and F4P159 sequences 396 
respectively are K and R), and further studies aim to more accurately delineate the heparin 397 
binding domains within regions of P159.   398 
Fucoidan, a sulfated polysaccharide of non-mammalian origin, inhibited the interaction 399 
between heparin and F3P159 and F4P159. It is generally the case that heparin-binding proteins also 400 
interact with fucoidan due to its high sulfate density and branched, comb-like structure, which 401 
contrasts with the linear structure of mammalian glycosaminoglycans (Patankar et al., 1993). 402 
Chondroitin sulfate A and B and mucin did not competitively inhibit the ability of heparin to 403 
bind P159 fragments F3P159 and F4P159; heparan sulfate, a less sulfated version of heparin, only 404 
slightly inhibited these interactions. Chondroitin sulfate B is similar in structure to heparin and 405 
heparan sulfate in that it contains a backbone of iduronate residues yet failed to act as a 406 
competitive inhibitor. Collectively, these observations suggest that the degree of sulfation is a 407 
key component in F3P159 and F4P159 binding heparin.   408 
In conclusion, evidence presented here indicates that P159 is a proteolytically processed, 409 
heparin binding surface protein of M. hyopneumoniae and that the C-terminal half of P159 410 
houses at least 2 heparin-binding domains located within F3P159 and F4P159 respectively. We 411 
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show that i) M. hyopneumoniae adheres intimately to the surface of PK15 cells where microvilli 412 
predominate, ii) heparin blocks the ability of this pathogen to adhere to PK15 cells and iii) 413 
regions within P159 are intimately involved in adherence to PK15 cells. Despite possessing 414 
limited coding capacity, evidence of differences in strain virulence (Vicca et al., 2003), cleavage 415 
of key surface proteins (Djordjevic et al., 2004), and our recent report that key surface proteins 416 
bind glycosaminoglycans (Jenkins et al., 2006) suggests that subtle changes in surface protein 417 
sequences may have significant ramifications for disease caused by M. hyopneumoniae. 418 
 419 
Experimental procedures 420 
Bacterial strains and growth conditions.  421 
M. hyopneumoniae strain 232 (Zhang et al., 1995) was a kind gift from F. C. Minion. Two strain 422 
J isolates were used in these studies; NCTC 10110 was used for immunoblot experiments and a 423 
low passage isolate derived from ATCC 27715 was used for infection studies of PK15 cells. The 424 
ATCC 27715 strain was kindly provided by P. Valentin-Weigand, University of Veterinary 425 
Medicine Hannover, Germany. A description of M. hyopneumoniae strains Beaufort, Sue and 426 
C1735/2 and their source has been described previously (Scarman et al., 1997). M. 427 
hyopneumoniae was grown in 0.22 μm filter sterilized modified Friis broth (Friis, 1975) and 428 
harvested as described previously (Djordjevic et al., 2004). For growth studies, sterile tubes 429 
containing 6 ml of Friis broth were simultaneously inoculated with 300 μl of M. hyopneumoniae 430 
strain 232 culture and incubated for 8, 16, 24, 28, 32, 40, 48, 56 and 72 h as described previously 431 
(Djordjevic et al., 1994). Escherichia coli M15 [pREP4] cells (Qiagen, Alameda, California) 432 
were grown at 37oC in Luria-Bertani medium (Sambrook et al., 1989). When appropriate, 433 
antibiotics were used at the following concentrations: ampicillin 100 μg/ml and kanamycin 25 434 
μg/ml. Protein expression was induced by the addition of 100 μM isopropyl- -D-435 
thiogalactopyranosidase (IPTG).  436 
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 437 
Proteomic analyses: 2-D gel electrophoresis and postseparation analyses.  438 
Two-dimensional gel electrophoresis (2-DGE) was carried out as described previously 439 
(Cordwell et al., 1997).  Conditions used for the solubilisation of M. hyopneumoniae proteins, 440 
isoelectric focusing and SDS-PAGE have been described previously in detail (Djordjevic et al., 441 
2004).  Briefly, M. hyopneumoniae bacterial cells were resuspended in 1 ml of sample buffer for 442 
each 0.1 g of bacterial pellet. Cells were disrupted with a Microson Ultrasonic sonicator 443 
(Misonix, Farmingdale, New York) for 6 x 30 sec at a power setting of 14 W and centrifuged 444 
(120 min, 50 000 x g) in a Beckman TL100 ultracentrifuge (Beckman Coulter, Fullerton, 445 
California). A total of 250 μg of M. hyopneumoniae protein extract was diluted with sample 446 
buffer to a volume of 100 μl for application to the anodic end of each IPG strip in an applicator 447 
cup. Isoelectric focusing was performed on a Multiphor II electrophoresis unit (Amersham 448 
Biosciences, Piscataway, New Jersey) for 85 kVh at 20oC. IPG strips were detergent exchanged, 449 
reduced, and alkylated in buffer containing 6 M urea, 2% SDS, 20% glycerol, 5 mM tributyl 450 
phosphine, 2.5% (v/v) acrylamide monomer, a trace amount of bromophenol blue dye, and 375 451 
mM Tris-HCl (pH 8.8) for 20 min prior to loading the IPG strip onto the top of a 8-18% 20 cm 452 
by 20 cm polyacrylamide gel. Second-dimension electrophoresis was carried out at 5oC using 3 453 
mA/gel for 2 h followed by 20 mA/gel until the bromophenol blue dye had run to the end of the 454 
gel. Gels were fixed in 40% methanol and 10% acetic acid for 1 h, stained overnight in Sypro 455 
Ruby (Molecular Probes, Eugene, Oregon) and images acquired using a Molecular Imager Fx 456 
apparatus (Bio-Rad Laboratories, Hercules, California). Gels were then double stained in 457 
Coomassie blue G-250. Protein spots were excised from gels using a sterile scalpel blade and 458 
placed into 96-well V bottom trays (Greiner Bio-One, Longwood, Florida). The methods used 459 
for post-separation analyses are as described previously (Djordjevic et al., 2004). A list of 460 
monoisotopic peaks corresponding to the mass of generated tryptic peptides was used to search a 461 
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modified translated version of the M. hyopneumoniae genome (Minion et al., 2004). N-terminal 462 
Edman sequencing was performed as previously described (Nouwens et al., 2000). 463 
 464 
Molecular analyses, cloning and expression.  465 
Plasmid DNA was prepared using a plasmid MidiPreparation kit (Qiagen, Alameda, California) 466 
as per manufacturer’s instructions. DNA sequence analysis was performed using the Sanger 467 
method. PCR was carried out using a DTCS Quickstart Master Mix (Beckman Coulter, 468 
Fullerton, California), according to the manufacturer’s instructions and analysed using a 469 
CEQ8000 Genetic Analyser (Beckman Coulter, Fullerton, California). Both pQE-9 specific 470 
primers and internal primers were used to initiate sequencing of DNA and were purchased from 471 
Sigma-Aldrich (Sydney, Australia). Hexahistidyl P159 fusion proteins were constructed using 472 
pPCR-Script (Stratagene, La Jolla, California) and pQE-9 (Qiagen, Alameda, California) cloning 473 
vectors. Primer sequences used to amplify each of the four fragments are given in Table 1. The 474 
underlined sequences correspond to the following restriction sites: SalI in the forward primers 475 
and PstI in the reverse primers. Recombinant proteins F1P159-F4P159 span nucleotides 91-791 476 
(amino acids 31-264), 792-1557 (amino acids 265-519), 1675-2727 (amino acids 558-909) and 477 
2875-4215 (amino acids 958-1405) respectively within the p159 gene sequence (accession 478 
number AF279292). PCR was carried out using Expand DNA Polymerase Enzyme (Roche, 479 
Basel, Switzerland) on a PC-960 thermocycler (Corbett Research, Mortlake, Australia). The 480 
template for the amplification of the entire p159 gene was M. hyopneumoniae 232. The resulting 481 
4233 bp amplicon was cloned into the pCR2.1 TA plasmid (Invitrogen, Carlsbad, California). 482 
The nine tryptophan-encoding TGA codons present in this ORF were converted to TGG by site-483 
directed mutagenesis using the QuikChange Site Directed Mutagensis Kit (Stratagene, La Jolla, 484 
CA) according to the manufacturers suggested protocol. The resulting clone was designated 485 
p110SDM c1. Amplification and site directed mutagenesis primers are indicated in Table 1. PCR 486 
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fragments were digested with SalI and PstI and cloned into SalI and PstI-digested pPCR-Script 487 
plasmid (Stratagene, La Jolla, California). Constructs with the proper fragment orientation were 488 
identified by restriction digestion and DNA sequence analysis and were designated p159PCR1-489 
4. Regions of p159 within p159PCR1-4 were digested with SalI and PstI and cloned into pQE-9 490 
(Qiagen, Alameda, California) using T4 DNA ligase (Roche, Basel, Switzerland) and 491 
transformed into E. coli M15 [pREP4] cells (Qiagen, Alameda, California) by electroporation 492 
using a Gene Pulsar (Bio-Rad Laboratories, Hercules, California) and the pre-set E. coli protocol 493 
at 2.5 kV. Correct constructs were identified as above and designated p159QE1-4. Protein 494 
expression was induced by the addition of 100 μM IPTG and proteins were purified using Ni-495 
NTA agarose as per the manufacturer’s instructions (Qiagen, Alameda, California). The 496 
presence of possible transmembrane domains was investigated using the TMPred program 497 
available via the Swiss European Molecular Biology Network (EMBnet) website 498 
(www.ch.embnet.org/software/TMPRED_form.html). 499 
 500 
Latex bead preparation and PK15 cell culture.  501 
As per previously published methods (Dombek et al., 1999; Molinari et al., 1997), latex beads (3 502 
μm; Sigma-Aldrich, St. Louis, Missouri) were coated with purified recombinant P159 fragments 503 
F1P159-F4P159. Briefly, 10
8 bead particles in 50 μl PBS were incubated with 5 μg of purified 504 
proteins in PBS overnight at 4oC. After washing steps, free binding sites on the bead surface 505 
were blocked by incubation with 200 μl of 10 mg/ml BSA in PBS for 1 h at room temperature. 506 
The efficiency of particle loading was verified by fluorescence-activated cell sorter analysis with 507 
anti-F1P159-F4P159 rabbit serum (results not shown). Beads were washed and the volume adjusted 508 
to 2.5 ml with Dulbecco modified Eagle medium (Invitrogen, Karlsruhe, Germany) with HEPES 509 
and 1% foetal calf serum. PK15 cells (American type culture collection certified cell line 33) 510 
were seeded on 12-mm-diamater glass coverslips (Nunc, Wiesbaden, Germany) placed on the 511 
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bottom of 24-well tissue culture plates (Nunc, Wiesbaden, Germany) at 1.5 x 105 cells per well 512 
and allowed to grow to semi-confluent monolayers at 37oC in a 5% CO2 atmosphere. After 513 
addition of 250 μl of the bead suspension, the cells were incubated for 2, 4, 7 and 22 h at 37oC in 514 
a 5% CO2 atmosphere.  Cells were washed three times with PBS to remove unbound beads. 515 
Cells were either processed for scanning electron microscopy (Molinari et al., 1997) or for 516 
double immunofluorescence microscopy as described below. Further studies were conducted 517 
pre-incubating the latex beads with a saturating concentration of heparin (500 μg/ml), purified 518 
F1P159, F2P159, F3P159, and F4 P159 proteins (1 μg each), or anti-F1P159-F4P159 sera (25 μg) 519 
separately for 1h at 37oC in a 5% CO2 atmosphere before addition to the PK15 cells. 520 
 PK15 cells were seeded on 12-mm-diamater glass coverslips placed on the bottom of 24-521 
well tissue culture plates at 1.5 x 105 cells per well and allowed to grow to semi-confluent 522 
monolayers at 37oC in a 5% CO2 atmosphere. A 5 ml fresh M. hyopneumoniae (strain J, ATCC 523 
27715) culture was centrifuged at 10,000  g and resuspended in 100 μl of Dulbecco modified 524 
Eagle medium (Invitrogen, Karlsruhe, Germany) with HEPES and 1% foetal calf serum. 10 μl of 525 
M. hyopneumoniae suspension per well was added to 0.5 ml of confluent PK15 cells and 526 
incubated at 37oC in a 5% CO2 atmosphere for 2 h. The wells were then prepared for electron 527 
microscopy as reported previously (Molinari et al., 1997). Additional experiments where M. 528 
hyopneumoniae was pre-incubated with a saturating concentration of heparin (500 μg/ml), 529 
purified F1P159, F2P159, F3P159, and F4P159 proteins (1 μg each), or anti-F1P159-F4P159 sera (25 μg) 530 
separately for 1h at 37oC in a 5% CO2 atmosphere before addition to the PK15 cells were 531 
conducted. 532 
 533 
Antisera, immunotechniques and microscopy.  534 
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Antisera to each fragment of P159 were generated by subcutaneous immunization of New 535 
Zealand White rabbits with hexahistidyl-tagged products purified by nickel-affinity 536 
chromatography. Pre-immune sera were collected prior to immunization for the preparation of 537 
control serum. Rabbits were then each immunized on two occasions 21 days apart using 538 
Freund’s incomplete adjuvant (Sigma-Aldrich, St. Louis, Missouri), and immune responses 539 
monitored by immunoblotting. Rabbits were euthanased, and serum collected as described 540 
previously (Wilton et al., 1998). Horse radish peroxidase-conjugated sheep anti-rabbit 541 
immunoglobulin antibodies were purchased commercially (Chemicon, Temecula, California). 542 
 M. hyopneumoniae whole cell protein preparations and purified hexahistidyl F1P159-543 
F4P159 proteins along with M. hyopneumoniae growth assay samples were subjected to 544 
electrophoresis on 12% SDS-PAGE gels as described previously (Laemmli, 1970). After 545 
electrophoresis, proteins were electrophoretically transferred onto polyvinylidene difluoride 546 
membrane using a Hoefer Scientific TE Series Transphor Electrophoresis Unit (Hoefer, San 547 
Francisco, California) as described previously (Burnette, 1981). Immunoblotting experiments 548 
were performed with rabbit polyclonal antibodies raised against F1P159-F4P159, either separately 549 
or pooled. Peroxidase conjugated sheep anti-rabbit was used as the secondary antibody and 550 
detected using diaminobenzidine (DAB; Sigma-Aldrich, St. Louis, Missouri). 551 
 PK15 cells (after incubation with the coated latex beads) were washed with PBS and 552 
then fixed by the addition of 0.5 ml/well of pre-cooled fixation buffer (1% paraformaldehyde in 553 
PBS), the tray was placed on ice for 1 h and then stored at 4oC overnight. The PK15 cells were 554 
blocked by the addition of 200 μl/well of PBS with 10% FCS and incubated for 30 min at room 555 
temperature. The blocking solution was then removed and the cells incubated separately with 556 
200 μl/well of the anti-F1P159-F4P159 rabbit polyclonal antibodies (40-50 μg/ml) for 45 min at 557 
room temperature. Cells were incubated with goat anti-rabbit Alexa 488 (green) (Molecular 558 
Probes, Eugene, Oregon) for 1h at room temperature and subsequently washed with PBS. Cells 559 
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were permeabilized with Triton X-100 (200 μl/well of a 0.1% triton X-100 in PBS solution) for 560 
5 min at room temperature, washed in PBS, followed by incubation with 200 μl/well of the anti-561 
F1-F4 rabbit polyclonal antibodies (40-50 μg/ml) for 45 min at room temperature. After 562 
washing, cells were treated with goat anti-rabbit Alexa 568 (red) (Molecular Probes, Eugene, 563 
Oregon) for 1 h and washed three times in PBS. Some cells were further incubated with 200 μl 564 
of a 0.1 mg/ml Hoechst stain (Molecular Probes, Eugene, Oregon) solution in PBS for 5 min 565 
before being washed three times in PBS. Cells were then mounted onto a glass slide. After this 566 
labeling procedure, extracellular beads appear yellow/green whereas intracellular beads are 567 
stained orange/red. Images were recorded using a Zeiss inverted microscope 100 M with an 568 
attached Zeiss Axiocam HRc digital camera. 569 
 Immunogold labelling of whole M. hyopneumoniae cells was performed as follows: 570 
Parlodion/carbon coated 300 mesh nickel grids (Pro Sci Tech, Queensland, Australia) were 571 
floated on drops of M. hyopneumoniae (strain 232) suspension in a moist petridish for 2 min. 572 
The grids were then incubated for 1 min with phosphate buffer (pH 6.8) containing 1% BSA, 573 
0.5% Tween 20 and 0.02% sodium azide. The grids were then floated on drops of undiluted anti-574 
F2 and anti-F4 sera, pre-immune for control and post-immune for tests, and incubated at 37oC 575 
for 90 min. The grids were washed with phosphate buffer (pH 6.8) 3 x 5 min and then floated on 576 
drops of protein A gold (15 nm, BBInternational, Cardiff, UK) diluted 1:50 for 45 min. The 577 
grids were washed with phosphate buffer and distilled water and stained with 2% aqueous uranyl 578 
acetate (Merck, Whitehouse Station, New Jersey). The grids were blotted dry and examined 579 
under a Philips 208 transmission electron microscope.  580 
 581 
Trypsin treatment of M. hyopneumoniae 582 
M. hyopneumoniae cells (0.5 g) were treated with trypsin as described previously (Wilton et al., 583 
1998). Briefly, trypsin was added to cell suspensions of M. hyopneumoniae at trypsin 584 
 25 
concentrations of 0, 0.1, 0.5, 1, 3, 5, 10, 50 and 150 μg/mL and incubated at 37oC for 15 min. 585 
Cell suspensions were then lysed in sample buffer (60 mM Tris, pH 6.8; 1% [w/v] SDS; 1% 586 
[v/v] -mercaptoethanol; 10% [v/v] Glycerol and 0.01% [w/v] bromophenol Blue) and heated to 587 
95oC for 10 min. Lysates were analysed by SDS-PAGE and immunoblotting with a pool of 588 
F1P159-F4P159 antiserum. 589 
 590 
Heparin binding assays.  591 
Paraformaldehyde (1% paraformaldehyde in PBS) fixed M. hyopneumoniae strain 232 cells at an 592 
optical density of 0.04 (in 0.1 M NaHCO3, pH 9.5) or aliquots (100 μl) of recombinant proteins 593 
F1P159-F4P159 (5 μg/ml in 0.1 M NaHCO3, pH 9.5) were applied to 96-well polystyrene microtitre 594 
plates (Linbro/Titretek; ICN Biochemicals, Aurora, Ohio). The plates containing the M. 595 
hyopneumoniae cells were centrifuged at 2000  g for 10 min, while the plates containing 596 
recombinant proteins were allowed to adsorb overnight at room temperature. The wells were 597 
then blocked with 100 μl aliquots of PBS containing 2% (w/v) skim milk for 1 h at room 598 
temperature. Biotinylated heparin (Sigma-Aldrich, St. Louis, Missouri) in PBS containing 1% 599 
skim milk was next applied to the wells in 100 μl aliquots and incubated for 1.5 h at room 600 
temperature. After 3 washes with 0.05% (v/v) Tween20 in PBS, bound biotinylated heparin was 601 
detected using 100 μl aliquots of peroxidase conjugated streptavidin (Roche, Basel, Switzerland) 602 
diluted 1:3000 with a 1 h incubation at room temperature. The wells were washed as above prior 603 
to the addition of substrate solution (100 μl) containing 0.55 mg/ml 2,2’-azino-bis(3-604 
ethylebenzthiazoline-6-sulfonic acid) diammonium salt (ABTS; Sigma-Aldrich, St. Louis, 605 
Missouri) in 0.1 M citrate, 0.2 M phosphate, pH 4.2, containing 0.03% (v/v) hydrogen peroxide. 606 
The absorbance of the product formed was measured at 414 nm using a Multiskan Ascent 607 
ELISA plate reader (Thermo Labsystems, Franklin, Massachusetts). In other experiments, a 608 
competitive binding assay was used in which unlabeled glycosaminoglycans; heparin, fucoidan,  609 
 26 
heparan sulfate,  mucin, chondroitin sulphate A and chondroitin sulfate B (all from Sigma-610 
Aldrich, St. Louis, Missouri) were pre-incubated with biotinylated heparin for 15 min before the 611 
addition of 100 μl aliquots of the mixture to coated and blocked wells. Control experiments 612 
showed that none of the P159 fragments could bind to streptavidin-peroxidase or the ABTS 613 
solution, establishing that the heparin binding is not an artifact of binding to a compound used in 614 
the detection system. Graph construction and non-linear regression with one-site binding and 615 
one-site competition analysis was performed using GraphPad Prism version 4 (GraphPad 616 
Software, San Diego, California). 617 
 A cell pellet of E. coli M15 [pREP4] cells (Qiagen, Alameda, California) containing 618 
the pQE-9 F1P159-F4P159 plasmids from a 300 ml culture were re-suspended in a solution of 50 619 
mM DTT, 2% triton X-100, 1 mg/ml lysozyme. The suspension was subjected to sonication and 620 
then centrifuged at 16, 000  g for 15 min at 10
o
C and the supernatant was applied to a 7.5 ml 621 
heparin-agarose column (Sigma-Aldrich, St. Louis, Missouri) that had been pre-equilibrated 622 
with 0.01 M Tris-HCl (pH 7.6). The column was washed with 45 ml 0.01 M Tris-HCl (pH 7.6) 623 
and bound proteins eluted at a flow rate of 1 ml/min with a linear 0-0.5 M NaCl gradient in 0.01 624 
M Tris-HCl (pH 7.6). The peak fractions (from the wash and elution’s) at 280 nm absorbance 625 
were subjected to electrophoresis on 12% SDS-PAGE gels as described previously (Laemmli, 626 
1970). After electrophoresis, proteins were electrophoretically transferred onto polyvinylidene 627 
difluoride membrane using a Hoefer Scientific TE Series Transphor Electrophoresis Unit 628 
(Hoefer, San Francisco, California) as described previously (Burnette, 1981).  Immunoblotting 629 
experiments were performed using rabbit polyclonal antibodies raised separately to F1P159-630 
F4P159. Peroxidase conjugated sheep anti-rabbit was used as the secondary antibody and detected 631 
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Table 1. Sequences of primers used in this study.  787 
 788 
Designation Sequence Length 
(bp) 
Target 
F1 (F) GGGTCGACAATTCAGCGCTTAGATCC 26 p159 F1 F primer 
F2 (F) GGGTCGACCAAACAAGTCAAAGCTCAGAA 29 p159 F2 F primer 
F3 (F) GGGTCGACAAGACCTCAGAGGCAAGTAAT 29 p159 F3 F primer 
F4 (F) GGGTCGACCACAAAATAACAACTTTCCAA 29 p159 F4 F primer 
F1 (R) GGCTGCAGTCACCCTTTTTGATCTGTTGA 29 p159 F1 R primer 
F2 (R) GGCTGCAGTCATGGTGCTGTCTCTGGTGA 29 p159 F2 R primer 
F3 (R) GGCTGCAGTCAATCTTTTTCTTGGTCATG 29 p159 F3 R primer 
F4 (R) GGCTGCAGTCAATATTGATCCATAAAGGC 29 p159 F4 R primer 
713 GGGGGATCCATGAAGAAACAAATTCGCAAC 30 p159 F primer  
714 GGGGGATCCTTATTAAGAATAATTCTTAAAATATTGATCC 40 p159 R primer 
p110W_1014F CAGAAATTATCAATTGGTAGATGGTATAATGCGCCCCAAAG 41 p159 SDM primer 
p110W_1014R CTTTGGGGCGCATTATACCATCTACCAATTGATAATTTCTG 41 p159 SDM primer 
p110W_1213F GAAAACCTTAAATTAGTCTGGAAACTAATCGGGGC 35 p159 SDM primer 
p110W_1213R GCCCCGATTAGTTTCCAGACTAATTTAAGGTTTTC 35 p159 SDM primer 
p110W_1293F CTTGGTCAAACTTGGTTAATGGAAATAAG 29 p159 SDM primer 
p110W_1293R CTTATTTCCATTAACCAAGTTTGACCAAG 29 p159 SDM primer 
p110W_1323F GCAAACTAAAAGTTTGGAAATCCGAAATTAAG 32 p159 SDM primer 
p110W_1323R CTTAATTTCGGATTTCCAAACTTTTAGTTTGC 32 p159 SDM primer 
p110W_1342F CCAAAACCAGGATACAAACTGGGAAACCGAGCTAGCTTC 39 p159 SDM primer 
p110W_1342R GAAGCTAGCTCGGTTTCCCAGTTTGTATCCTGGTTTTGG 39 p159 SDM primer 
p110W_462F CAGGAAGTAATTTGGAGTTTTTCAAGG 27 p159 SDM primer 
p110W_462R CCTTGAAAAACTCCAAATTACTTCCTG 27 p159 SDM primer 
p110W_623F CTAAAAATTCATGGTTGGAATTATAGAACAC 31 p159 SDM primer 
p110W_623R GTGTTCTATAATTCCAACCATGAATTTTTAG 31 p159 SDM primer 
p110W_73F GCTTAAAAGAAAACTGGAGTAAAATATCAGCTGG 34 p159 SDM primer 
p110W_73R CCAGCTGATATTTTACTCCAGTTTTCTTTTAAGC 34 p159 SDM primer 
p110W_759F GCTTATGAATTAAAGGGTTGGACTTATCCAATTG 34 p159 SDM primer 
p110W_759R CAATTGGATAAGTCCAACCCTTTAATTCATAAGC 34 p159 SDM primer 
 789 
Restriction sites for SalI in the forward (F) primers and PstI in the reverse (R) primers used for 790 










Figure legends 800 
Fig. 1. 2-DGE and peptide mass fingerprint analysis of P159.  (A) 2-D gel (8-18% 801 
polyacrylamide gradient) of M. hyopneumoniae strain 232 whole cell lysate. Proteins were 802 
resolved using a pH 6-11 first dimension isoelectric focusing strip prior to SDS-PAGE. P159 803 
cleavage fragments P27, P52 and P110 identified by peptide mass mapping are indicated. Spot 804 
trains (commonly observed for proteins resolved by 2-DGE electrophoresis) may be due to bona 805 
fide posttranslational modifications that evoke a pI shift (e.g. phosphorylation) or are artifactual 806 
arising by non-enzymatic deamidation of Asn to Asp. (B) Peptide mass mapping was performed 807 
using MALDI-TOF (MS) analysis on tryptic digests of P159 proteins boxed in panel A. The N-808 
terminal sequence of P27 as determined by Edman degradation is underlined. The predicted 809 
transmembrane region is double underlined. (C) Diagrammatic representation of the P159 810 
molecule depicting P27, P110 and P52. The four P159 recombinant fragments (F1P159-F4P159) 811 
constructed for this study are also shown. The cleavage site between P27 and P110 is predicted 812 
to occur between amino acids 220-302 whilst cleavage between P110 and P52 is predicted to 813 
occur between amino acids 842-977. 814 
 815 
 816 
Fig. 2. Immunoblot analyses using F1P159, F2P159, F3P159, and F4P159 antisera. Panels A-D show 817 
whole cell protein extracts of M. hyopneumoniae strain 232 (lane 1) and a sample of purified 818 
F1P159, F2P159, F3P159, and F4P159 proteins (lane 2, panels A-D respectively) reacted with anti-819 
F1P159 (panel A), anti-F2P159 (panel B), anti-F3P159 (panel C), and anti-F4P159 sera (panel D). 820 
Antisera were diluted 1/100. All preparations were boiled for 5 min in Laemmli buffer. Black 821 
arrowheads indicate the position of recombinant proteins F1P159-F4P159. White arrowheads 822 
 32 
indicate the position of dominant cleavage fragments recognised by antisera in whole cell lysates 823 
of M. hyopneumoniae. The asterix (*) identifies a multimeric form of recombinant protein 824 
F4P159. An immunoblot containing comparable amounts of whole cell lysates of M. 825 
hyopneumoniae strain 232 harvested at different times during the growth cycle reacted with a 826 
pool of anti F1P159-F4P159 sera is shown in panel E. Lanes 1-9 correspond to M. hyopneumoniae 827 
cultures harvested at 8, 16, 24, 28, 32, 40, 48, 56 and 72 hours post inoculation respectively. An 828 
immunoblot containing comparable amounts of whole cell lysates of various M. hyopneumoniae 829 
strains reacted with a pool of anti F1P159-F4P159 sera is shown in panel F. Lane 1-5 were loaded 830 
with lysates of strains 232, J, SUE, C1735/2, and Beaufort respectively. 831 
 832 
Fig. 3. Localization of P159 cleavage products on the surface of M. hyopneumoniae strain 232. 833 
Panel A shows an immunoblot of whole cell preparations of freshly cultured M. hyopneumoniae 834 
strain 232 cells exposed to different concentrations of trypsin ranging from 0, 0.1, 0.5, 1, 3, 5, 835 
10, 50 and 150 μg/ml for 15 minutes (lanes 1-9 respectively) reacted with a pool of rabbit anti-836 
F1P159-F4P159 sera. Panels B-E show electron micrographs of intact, freshly cultured M. 837 
hyopneumoniae strain 232 cells labeled with pre-immune, control sera collected prior to 838 
immunization with recombinant proteins F2P159 and F4P159 (panels B and D respectively) or 839 
hyper-immune rabbit anti-F2P159 and anti-F4P159 sera (panel C and E respectively). Colloidal 840 
gold-conjugated anti-rabbit Ig (15 nm particles) was used to detect P159 cleavage fragments 841 
recognized by these sera. Cells were stained with 2% aqueous uranyl acetate. Arrows indicate 842 
gold particles. Bars = 500 nm. 843 
 844 
Fig. 4. Binding of biotinylated heparin to M. hyopneumoniae strain 232. Binding of biotinylated 845 
heparin to the surface of M. hyopneumoniae strain 232 is shown in panel A. Increasing 846 
concentrations of biotinylated heparin were added to 96-well microtitre plates coated with M. 847 
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hyopneumoniae strain 232. Figures shown are means + SEM of triplicate determinations, 848 
indicated by error bars. A ligand blot containing M. hyopneumoniae strain 232 whole cell lysate 849 
probed with biotinylated heparin is shown in panel B.  850 
 851 
Fig. 5. Binding of recombinant P159 fragments (F1P159-F4P159) to biotinylated heparin. 852 
Increasing concentrations of biotinylated heparin were added to 96-well microtitre plates coated 853 
with 5 μg/ml of each of the four P159 fragments.  represents the total binding and  represents 854 
non-specific binding measured by mixing the biotinylated heparin with a 50-fold excess (2.4 855 
mg/ml) of non-biotin labeled heparin prior to incubation with the recombinant P159 fragments. 856 
The specific binding curve, represented by the symbol , was obtained by subtracting non-857 
specific binding from the total binding values. Figures shown are means + SEM of triplicate 858 
determinations, indicated by error bars. Controls with specific antisera show that each protein 859 
was successfully coated to the ELISA plate. 860 
 861 
Fig. 6. Inhibition studies with various glycosaminoglycans. Different glycosaminoglycans were 862 
examined for their ability to inhibit the binding of recombinant P159 fragments to biotinylated 863 
heparin. Panel A shows how unlabeled heparin affects the ability of F1P159 ( ), F2P159 ( ), F3P159 864 
( ) and F4P159 ( ) to bind biotinylated heparin. Panels B and C show how unlabeled fucoidan , 865 
heparan sulfate , chondroitin sulfate A , and chondroitin sulfate B  affect the ability of 866 
F3P159 and F4P159 to bind biotinylated heparin respectively. Inset are inhibition curves showing 867 
an expansion of the optimal inhibition range of 0-600 μg/ml. In these experiments, varying 868 
concentrations (0-40 times the saturating concentration of 60 μg/ml) of glycosaminoglycan 869 
inhibitors were each pre-incubated with biotinylated heparin (60 μg/ml). Error bars represents 870 
mean values + SEM from triplicate experiments. 871 
 872 
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Fig. 7. Scanning electron micrographs depicting the interaction of M. hyopneumoniae with PK15 873 
cells. Panel A shows M. hyopneumoniae interacting with PK15 cells. Panel B shows the 874 
inhibition of M. hyopneumoniae adherence due to the presence of F4P159 protein (1 g). 875 
Adhering M. hyopneumoniae cells are indicated by an arrow. Panel C shows the inhibition of 876 
adherence due to the presence of heparin (500 g/ml). Scale bars are given at the bottom of each 877 
image. 878 
 879 
Fig. 8. Double immunofluorescence microscopy of PK15 cells exposed to latex beads coated 880 
with recombinant P159 proteins. Beads determined to reside intracellularly are identified with 881 
white arrows. Panel A shows PK15 cells incubated with F1P159 -coated latex beads after 22 h 882 
incubation. These images are indistinguishable from control images of PK15 cells exposed to 883 
naïve latex beads and show that F1P159 does not play a direct role in adherence. Panel B shows 884 
F2P159- coated latex beads after 7 h of incubation adhering to the surface of (yellow/green) and 885 
penetrating into (orange/red) PK15 cells. Panel C shows a similar image as depicted in B except 886 
the nucleus of the PK15 cells were stained with Hoechst stain. Panel D depicts the same image 887 
as panel C but with a different exposure time showing the extracellular (yellow/green) beads and 888 
the intracellular (orange/red) beads. Panel E shows F3P159-coated beads interacting with a cluster 889 
of PK15 cells after 4 h of incubation. Panel F depicts F4P159-coated beads interacting with PK15 890 
cells after 7 h incubation. Beads were identified on the surface (yellow/green beads) and within 891 
(orange/red beads) PK15 cells. 892 
 893 
Fig. 9. Scanning electron micrographs depicting the interaction of latex beads separately coated 894 
with recombinant P159 fragments F2P159 and F4P159 with PK15 cells. Panels A and B depict 895 
F2P159- and F4P159- coated latex beads adhering to and residing within PK15 cells respectively. 896 
Panel C represents an enlargement of the area (marked by an arrow) in panel A showing an 897 
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F2P159- coated bead adhering to and another within a PK15 cell 2 h after incubation. Similarly, 898 
panel D represents the arrow marked area in panel B showing a F4P159- coated bead adhering to 899 
and another within a PK15 cell 2 h after incubation. Panels E and F depict F4P159- coated latex 900 
beads adhering to and residing inside PK15 cells 2 and 4 h after incubation respectively. The 901 
scale bars are given at the bottom of each image. 902 
 903 
Fig. 10. Inhibition of binding of F2P159 and F4P159- coated latex beads to PK15 cells. F2P159- 904 
coated latex beads pre-incubated with F2P159 bound poorly to PK15 cells (panel A). F4P159- 905 
coated latex beads pre-incubated with F4P159 protein bound poorly to PK15 cells (panel B). An 906 
adherent bead is highlighted by an arrow. F4P159- coated latex beads pre-incubated with heparin 907 
bound poorly to PK15 cells (panel C). Scale bars represent 10 μm. Panel D summarises data 908 
derived from three individual assays (20 cells counted per assay). Error bars represent the 909 
standard deviation. Latex beads were pre-incubated with a saturating concentration of heparin 910 
(500 μg/ml) or protein (1 μg) for 1h before addition to the PK15 cells. Numbers of adhering 911 
(extracellular) and invasive (intracellular) beads were quantified by double immunofluorescence 912 
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